INTERGRASE INHIBITORS- WHAT S NEW?
|
|
- Herbert Douglas
- 5 years ago
- Views:
Transcription
1 INTERGRASE INHIBITORS- WHAT S NEW? Professor Margaret Johnson Royal Free London Foundation Trust October 2018
2 Targeting the HIV life-cycle NEW HIV VIRON MATURATION CO-RECEPTOR BINDING FUSION BUDDING CD4 BINDING ssrna Assembly HIV viron Reverse transcription of viral RNA genome Translation gp120 CD4 Chemokine Co-receptor (CCR5 or CXCR4) Proviral DNA Viral RNAs Integration Transcription CCR5, C-C chemokine receptor type 5; CD4, cluster of differentiation 4; CXCR4, C-X-C chemokine receptor type 4; ssrna, single-strand RNA. Figure adapted from Reyskens et al. Biochim Biophys Acta 2014;1842:
3 Chemical Structure of INSTIs Mechanism of Action Metal-Chelating Core Halogenated Phenyl Ring Side Chain RAL EVG DTG BIC Metal-Chelating Core: Oxygen atoms chelate a pair of Mg 2+ ions and bind the integrase catalytic active site Halogenated Phenyl: Interacts with the integrase pocket that is normally occupied by the terminal 3 base of viral DNA 1. Lazerwith SE, et al. ASM Poster # Gallant J, et al. ASM Poster # Tsiang M, et al. ASM Poster # Tsiang M, et al., AAC 2016;60:
4 Integrase inhibitors perform as well as, or better than, other classes of ARV PoC ART monotherapy: maximum change in HIV RNA (log 10 ) over 7 14 days Maximum HIV RNA reduction (Log 10 ) 900 mg BID 25 mg QD 200/100 mg or 400/100 BID 600/100 mg BID 500 mg QD 300 mg BID 300 mg BID 600 mg BID 300 mg QD 40 mg QD 10 mg single-dose 200 mg QD 600 mg BID 50 mg QD 50/100 mg QD 30 mg QD 100 mg QD 40 mg QD 1200 mg /100 mg Q12H 300 mg BID 100 mg BID NNRTIs PIs NRTIs INSTIs MIs AI EIs *Single dose. Mean / median value as available. Day 21. Week 24. **Day 28. NB: Some of the antiviral effects were observed at doses different to the licensed dose of the ARV for treatment-naïve individuals AI = attachment inhibitor; ART = antiretroviral therapy; BID = twice daily; EI = entry inhibitor; INSTI = integrase strand transfer inhibitor; MI = maturation inhibitor; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; PoC = proof of concept; QD = once daily; TAF = tenofovir alafenamide fumarate; TDF = tenofovir disoproxil fumarate. See slide notes for references.
5 INSTI-Containing Regimens Were Associated With Fewer Discontinuations Due to AEs Than EFV/TDF/FTC in Treatment-Naïve Patients Discontinuations for AEs (%) DTG-, EVG- and RAL-containing regimens were all associated with fewer discontinuations due to AEs than EFV/TDF/FTC over the long term Data comparing BIC with EFV or RPV are not available EVG/c/ TDF/FTC Discontinuations from Phase 3 studies of treatment-naïve patients: INSTIs vs NNRTIs 7 EFV/ TDF/FTC Study 102 (144 weeks) 1 3 DTG/ ABC/3TC 11 EFV/ TDF/FTC SINGLE (144 weeks) 2 5 RAL + TDF/FTC 7 EFV/ TDF/FTC STARTMRK-1 (156 weeks) 3 3TC = lamivudine; ABC = abacavir; AE = adverse event; BIC = bictegravir; DTG = dolutegravir; EFV = efavirenz; EVG/c = elvitegravir/cobicistat; FTC = emtricitabine; INSTI = integrase strand transfer inhibitor; NNRTI = non-nucleoside reverse transcriptase inhibitor; RAL= raltegravir; RPV = rilpivirine; TDF = tenofovir disoproxil fumarate. Adapted from: 1. Wohl et al. J Acquir Immune Defic Syndr 2014;65:e118 20; 2. Walmsley et al. J Acquir Immune Defic Syndr 2015;70:515 9; 3. Rockstroh et al. Clin Infect Dis 2011;53:
6 Discontinuations Due to AEs Were Lower With INSTI-Based Regimens vs With Boosted PI-Based Regimens in Treatment-Naïve Patients Discontinuations for AEs (%) INSTIs have been associated with fewer discontinuations due to AEs than boosted DRV and ATV in treatment-naïve patients Data comparing BIC with any of the PIs are not available DTG + 2NRTI 6 DRV/r + 2NRTI Discontinuations from Phase 3 studies in treatment-naïve patients: INSTIs vs PIs 4 7 DTG/ ATV/r ABC/3TC+ TDF/FTC 6 FLAMINGO ARIA Study 103 WAVES ACTG5257* (96 weeks) 1 (48 weeks) 2 (144 weeks) 3 (48 weeks) 4 (96 weeks) 5 *Rates reflect the % of patients with toxicity-associated discontinuations. 3TC = lamivudine; ABC = abacavir; AE = adverse event; ATV = atazanavir; ATV/r = atazanavir/ritonavir; BIC = bictegravir; DRV/r = darunavir/ritonavir; DTG = dolutegravir; EVG/c = elvitegravir/cobicistat; FTC = emtricitabine; INSTI = integrase strand transfer inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; RAL = raltegravir; TDF = tenofovir disoproxil fumarate. 9 EVG/c/ ATV/r + TDF/FTC TDF/FTC 2 7 EVG/c/ ATV/r + TDF/FTC TDF/FTC 1 RAL + TDF/FTC 5 14 DRV/r + ATV/r + TDF/FTC TDF/FTC Adapted from:1. Molina et al. Lancet HIV 2015; 2:e127 36; 2. Orrell et al. Lancet HIV 2017;4:e536 46; 3. Clumeck et al. J Acquir Immune Defic Syndr 2014;65:e121 4; 4. Squires et al. Lancet HIV 2016;3:e410 20; 5. Lennox et al. Ann Intern Med 2014;161:
7 Treatment- Experienced Treatment- Naive B/F/TAF Phase 3 Clinical Development Program * Through 48 weeks, B/F/TAF demonstrated high HIV suppression rates, non-inferior efficacy to DTG- & PI-based regimens with zero resistance development. Registrational Special Populations Study 1489 (N=600) 1,2 vs. DTG/ABC/3TC Study 1490 (N=600) 1,3 vs. DTG + FTC/TAF Study 1878 (N=520) 1,4 vs. boosted DRV/ATV + 2 NRTIs Study 1844 (N=520) 1,5 vs DTG/ABC/3TC Study 1961 (N=470) Women 6 E/C/F/(TAF/TDF) or ATV+RTV+FTC/TDF Study 1474* (N=100) Paediatrics 7 2 NRTIs + 3rd agent B/F/TAF * Study 1474 is a Phase 2/3 and has a single arm 1. Gilead Sciences. Biktarvy US Prescribing Information. February Gallant J, et al. Lancet 2017;390: Sax P, et al. Lancet 2017;390: Daar E, et al. ID Week San Diego, CA. Oral LB Molina JM, et al. CROI Boston, MA. Oral Kityo C, et al. CROI Boston, MA. Poster Gaur A, et al. CROI Boston, MA. Poster 844 7
8 Intergrase Cross-Resistance Profile Comparison of INSTI cross-resistance using a representative panel of HIV with integrase mutants from clinical isolates and site directed mutations Single Primary Mutations** Fold Change vs WT IN Genotype BIC DTG EVG RAL E92Q T97A F121Y* Y143C* Y143R Q148H* Q148K* Q148R* N155H* R263K* More Complex Resistance Patterns Fold Change vs WT IN Genotype BIC DTG EVG RAL T97A, N155H E138K, Q148R > G140A, Q148R > G140S, Q148H >150 >143 G140S, Q148H, G163K >150 >143 L74M, G140C, Q148R >150 >143 T97A, G140S, Q148H >150 >143 E138K, G140S, Q148H >150 >143 E138A, G140S, Q148H >150 >143 E138K, G140A, Q148K >150 >143 * Site directed mutants; **Single mutants from the USPI are bolded above Tsiang et al, Antimicrobial Agents and Chemotherapy, 2006 BIC or EVG < 2.5 BIC or EVG BIC or EVG 10 Andreatta K et al. CROI Boston, MA. Poster #546 RAL <1.5 RAL RAL >10 White K, et al. CROI Boston, MA. Poster 532 DTG <4 DTG 4-13 DTG >13 Gilead Sciences. Data on File 8
9 2014: Integrase inhibitors were added as preferred options for Treatment-Naive Patients in International Guidelines DHHS 1 (Dept. of Health and Human Services) NNRTI-based therapy EFV/TDF/FTC or 3TC EFV+ABC ab /3TC or FTC or RPV bc /TDF/FTC or 3TC Ritonavir-boosted PI-based therapy ATV/r or DRV/r + TDF/FTC or 3TC ATV/r + ABC a /3TC or 3TC INI-based therapy DTG + ABC a /3TC or FTC DTG + TDF/FTC or 3TC EVG/cobi/TDF/FTC d RAL + TDF/FTC or 3TC IAS-USA 2 (International Antiviral Society USA Panel) EFV e + TDF/FTC EFV e + ABC af /3TC g RPV h /TDF/FTC ATV/r ij + TDF/FTC ATV/r ij + ABC af /3TC g DRV/r j + TDF/FTC DTG k + ABC af /3TC DTG k + TDF/FTC RAL k + TDF/FTC EVG k /cobi/tdf/ftc EACS 3 (European AIDS Clinical Society) EFV l + TDF/FTC or ABC/3TC abf RPV bcm + TDF/FTC or ABC/3TC abf ATV/r n or DRV/r n + TDF/FTC or ABC/3TC abf EVG/cobi/TDF/FTC do DTG + TDF/FTC or ABC/3TC a RAL + TDF/FTC or ABC/3TC a a Only if HLA-B*5701 negative. b only if VL<100,000 c/ml. c Only if CD4>200 cells/mm 3. d Only for patients with pre-treatment CrCl>70ml/min. e Take on an empty stomach, preferably at bedtime. f ABC has been associated with increased CV risk, although conflicting data; use with caution in patients with high CV risk. g Combination of ABC/3TC less efficacious with baseline HIV-1 RNA >100,000 copies/ml than combination of TDF/FTC when given with EFV or ATV/r. h RPV should not be given with proton pump inhibitors and should be taken consistently with a full meal. i Take with food. j avoid co-administration with H2-blockers or proton pump inhibitors if possible and, if not, follow specific doses/dose separation schedules recommended in prescribing information. k Avoid simultaneous administration with antacids or other divalent cations due to chelation of INI by the cation, thereby reducing absorption. l EFV not recommended to be initiated in pregnant women or women with no reliable and consistent contraception; continuation is possible if EFV is already started before pregnancy; not active against HIV-2 and HIV-1 group O strains. m PPI contraindicated, take H2 antagonists 12 hours before or 4 hours after RPV. n Coadministration with PPI is contraindicated for treatment-experienced persons; if co-administration unavoidable, close clinical monitoring is recommended and doses of PPI comparable to omeprazole 20mg should not be exceeded and must be taken approximately 12 hours prior to ATV/r. O Not to be initiated in persons with egfr<70ml/min; not to be initiated when egrf<90ml/min unless the preferred treatment. Adapted from: 1. DHHS Guidelines November 2014; 2. Gunthard HF et al. JAMA 2014;312: ; 3. EACS Guidelines version 7.1 November 2014.
10 2015: NNRTIs were relegated to alternative for Treatment-Naive Patients in International Guidelines DHHS 1 (Dept. of Health and Human Services) NNRTI-based therapy Now alternative Ritonavir-boosted PI-based therapy DRV/r + TDF/FTC or 3TC INI-based therapy DTG + ABC a /3TC or FTC DTG + TDF/FTC or 3TC EVG/cobi/TDF/FTC d RAL + TDF/FTC or 3TC IAS-USA 2 (International Antiviral Society USA Panel) EFV e + TDF/FTC EFV e + ABC af /3TC g RPV h /TDF/FTC ATV/r ij + TDF/FTC ATV/r ij + ABC af /3TC g DRV/r j + TDF/FTC DTG k + ABC af /3TC DTG k + TDF/FTC RAL k + TDF/FTC EVG k /cobi/tdf/ftc EACS 3 (European AIDS Clinical Society) EFV l + TDF/FTC or ABC/3TC abf RPV bcm + TDF/FTC or ABC/3TC abf ATV/r n or DRV/r n + TDF/FTC or ABC/3TC abf EVG/cobi/TDF/FTC do DTG + TDF/FTC or ABC/3TC a RAL + TDF/FTC or ABC/3TC a a Only if HLA-B*5701 negative. b only if VL<100,000 c/ml. c Only if CD4>200 cells/mm 3. d Only for patients with pre-treatment CrCl>70ml/min. e Take on an empty stomach, preferably at bedtime. f ABC has been associated with increased CV risk, although conflicting data; use with caution in patients with high CV risk. g Combination of ABC/3TC less efficacious with baseline HIV-1 RNA >100,000 copies/ml than combination of TDF/FTC when given with EFV or ATV/r. h RPV should not be given with proton pump inhibitors and should be taken consistently with a full meal. i Take with food. j avoid co-administration with H2-blockers or proton pump inhibitors if possible and, if not, follow specific doses/dose separation schedules recommended in prescribing information. k Avoid simultaneous administration with antacids or other divalent cations due to chelation of INI by the cation, thereby reducing absorption. l EFV not recommended to be initiated in pregnant women or women with no reliable and consistent contraception; continuation is possible if EFV is already started before pregnancy; not active against HIV-2 and HIV-1 group O strains. m PPI contraindicated, take H2 antagonists 12 hours before or 4 hours after RPV. n Coadministration with PPI is contraindicated for treatment-experienced persons; if co-administration unavoidable, close clinical monitoring is recommended and doses of PPI comparable to omeprazole 20mg should not be exceeded and must be taken approximately 12 hours prior to ATV/r. O Not to be initiated in persons with egfr<70ml/min; not to be initiated when egrf<90ml/min unless the preferred treatment. Adapted from: 1. DHHS Guidelines April 2015; 2. Gunthard HF et al. JAMA 2014;312: ; 3. EACS Guidelines version 7.1 November 2014.
11 Key Preferred and Alternative Initial Regimens for Adults: 2018 Preferred/recommended *Regimens or components may have restrictions on use, such as HLA genotype, viral load, CD4 cell count or co-morbidities. The recommended prodrug of tenofovir (TDF or TAF) and PK booster (ritonavir [/r] or cobicistat [/c]) are listed in the table 3TC, lamivudine; ABC, abacavir; ATV, atazanavir; AZT, zidovudine; /c, cobicistat boosted; DRV, darunavir DTG, dolutegravir; EFV, efavirenz; EVG, elvitegravir; FTC, emtricitabine; HLA, human leukocyte antigen; INI, integrase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; NVP, nevirapine; PI, protease inhibitor; PK, pharmacokinetic; /r, ritonavir boosted; RAL, raltegravir; RPV, rilpivirine; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate Recommended in certain clinical situations Regimen* IAS-USA 1 DHHS2 EACS3 DTG/ABC/3TC DTG + tenofovir/ftc TAF TDF or TAF TDF or TAF INI + BIC/tenofovir/FTC TAF NRTIs RAL + tenofovir/ftc TAF or TDF EVG/c/tenofovir/FTC TAF or TDF TDF or TAF TDF or TAF RAL + ABC/3TC EFV/tenofovir/FTC TDF TDF or TAF TDF NNRTI + EFV + ABC/3TC NRTIs RPV/tenofovir/FTC TDF or TAF TDF or TAF TDF or TAF Boosted /r or /c /r or /c Boosted ATV + PI + tenofovir/ftc TDF or TAF TDF or TAF NRTIs Boosted ATV + ABC/3TC /r or /c /r or /c Boosted DRV + /r or /c /r or /c /r or /c tenofovir/ftc TDF or TAF TDF or TAF TDF or TAF Boosted DRV + ABC/3TC /r or /c /r or /c Alternative Not listed WHO guidelines 4, 5 recommend different regimens Preferred (as stated in 2018 guidelines): DTG + 3TC + TDF 5 EFV TDF + 3TC (or FTC) 5 Alternative **: EFV TDF + [3TC or FTC] 4 Special situations **: EFV 600 a + AZT + 3TC 4 PI /r b + TDF + 3TC (or FTC) 4 Adapted from: 1. Saag MS, et al. JAMA 2018;320: DHHS Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents, October 2017; 3. EACS Guidelines Version 9.0, October 2017; 4. Doherty M. The role of DTG based regimens in first- and second-line HIV treatment and PEP Updated WHO recommendations. Presented at 22 nd International AIDS Conference, Amsterdam, The Netherlands, July 23-27, 2018; 5. Updates Recommendations on First-Line and Second-Line Antiretroviral Regimens and Post- Exposure Prophylaxis and Recommendations on Early Infant Diagnosis of HIV, July 2018
12 Emerging Evidence for Use of Two-drug Regimens in Patients Switching for Reasons Other than Virologic Failure All guidelines mention switching for AEs or DDIs. Other reasons in IAS-USA, DHHS and EACS guidelines include long-term toxicity of older ARVs and dosing strategy/convenience IAS-USA 1 DHHS 2 EACS 3 WHO Review ARV history and resistance tests if available Older regimens may be switched to an STR TDF/FTC may be switched to TAF/FTC in order to minimize renal or bone AE Within-class switch may be possible without resistance data if genetic barrier is similar or higher Virologic Suppression: Patients may switch from 3DR to a 2DR in the setting of VS, using DTG/RPV, a boosted PI with 3TC, or DTG + 3TC can be used in patients with no prior virologic failure or transmitted drug resistance Review ARV history and resistance tests if available Within-class switch if no resistance to new ARV Between-class switch if other ARVs remain active Class-sparing strategies: DTG + RPV boosted PI + 3TC Monotherapy not recommended Alternative ARVs in the case of specific AEs also listed in Table 15 (DHHS) Review ARV history, tolerability and resistance if available If no prior VF or resistance, switch to any other preferred 1 st line regimen Replace individual ARV if new drug is active and has similar or greater genetic barrier Switch from boosted PI to unboosted ATV, NNRTI or INI only if backbone NRTIs fully active Class-sparing strategies: DTG + RPV boosted [DRV or ATV] + 3TC DRV/r monotherapy only if dual therapy not possible WHO does not recommend routine resistance testing An overall sequence of regimens is provided irrespective of reason to switch (see VF) Alternative ARVs in the case of specific AEs also listed IAS-USA, DHHS and EACS guidelines recommend using treatment history and resistance testing to guide ARV substitutions where possible AE, adverse event; STR, single-tablet regimen; VS, virologic suppression; 3DR, three drug regimen; 2DR, two drug regimen Adapted from: 1. Saag MS, et al. JAMA 2018;320: ; DHHS Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents, Oct. 2017; 3. EACS Guidelines Version 9.0, Oct WHO Consolidated Guidelines on the Use of ARV Drugs for Treating and Preventing HIV Infection, July 2016
13 SWORD-1 and -2: Phase III Study Design Identically designed, randomised, multicentre, open-label, parallel-group, non-inferiority studies Screening VL <50 c/ml on INI, NNRTI, or PI + 2 NRTIs 1:1 Early-switch phase Late-switch phase Continuation phase DTG + RPV (N=513) DTG + RPV DTG + RPV CAR (N=511) Day 1 Week 52 Week 148 Inclusion criteria On stable CAR 6 months before screening 1st or 2nd ART with no change in prior regimen due to VF Confirmed HIV-1 RNA <50 c/ml during the 12 months before screening HBV-negative Primary endpoint at 48 weeks: subjects with VL <50 c/ml (ITT-E snapshot) * *8% non-inferiority margin for pooled data. -10% non-inferiority margin for individual studies HBV, hepatitis B virus; ITT(-E), intent to treat (- exposed) INI, integrase inhibitor; ITT-E, intent to treat exposed; NRTI, nucleoside reverse transcriptase inhibitor VF, virologic failure; VL, viral load Adapted from Llibre JM, et al. Lancet 2018;391:839 49
14 HIV-1 RNA <50 c/ml, % SWORD-1 and -2: Virologic Suppression* at Week 48 and Week Durable efficacy maintained through 100 weeks in early switch group Virologic success 93 n (%) <1 DTG + RPV, D1 W48, early switch (n=513) DTG + RPV, D1 W100, early switch (n=513) DTG + RPV, W52 W100, late switch (n=477) Virologic non-response *FDA Snapshot; Lost to follow-up, n=3; protocol deviation, n=5 (prohibited medication use, n=3 pregnancy, n=2); withdrawal of consent, n=18 (subject relocated, n=5; travel burden, n=2; other n=9); and investigator discretion, n=2 D, day; FDA, US Food and Drug Administration; W, Week Early-switch group DTG + RPV Week 48 1 DTG + RPV Week No virologic data Late-switch group DTG + RPV Week Virologic success 486 (95) 456 (89) 444 (93) Virologic non-response 3 (<1) 13 (3) 10 (2) Data in window, not <50 c/ml 0 5 (<1) 3 (<1) Discontinued for lack of efficacy 2 (<1) 7 (1) 3 (<1) Discontinued while not <50 c/ml 1 (<1) 1 (<1) 0 Change in ART (<1) No virologic data 24 (5) 44 (9) 23 (5) Discontinued because of AE or death 17 (3) 27 (5) 11 (2) Discontinued for other reasons 7 (1) 17 (3) 9 (2) Missing data during window but on study (<1) Adapted from 1. Llibre J, et al. Lancet 2018;391: Aboud M, et al. IAS Poster THPEB047
15 Emerging Evidence for Use of Two-drug Regimens in Treatment-naïve Patients IAS-USA 1 DHHS 2 EACS 3 2-drug regimens for treatment-naïve patients* Recommended only if patient cannot take ABC, TAF or TDF: DRV/r or /c + [3TC or FTC] DRV/r or /c + [RAL or DTG]; may be less effective if CD4 <200 cells/mm 3 or HIV-1 RNA >100,000 c/ml Regimens to consider when ABC, TAF, and TDF cannot be used: LPV/r + 3TC DRV/r + RAL; only if CD4 count >200 cells/mm 3 and HIV-1 RNA <100,000 c/ml Alternative regimens include: DRV/r or /c + RAL; only if CD4 count >200 cells/mm 3 and HIV-1 RNA <100,000 c/ml Patients taking PrEP (TDF/FTC) with suspected HIV infection should add DRV/r or /c and/or DTG to TDF/FTC pending HIV-1 RNA level and resistance testing results PEP is recommended as soon as possible, before HIV-1 RNA level and resistance testing results. RAL or DTG] + TDF/FTC is recommended Immediate treatment required, before HIV-1 RNA and/or resistance test results available* Recommended regimens: DRV/r or /c + [TDF or TAF]/FTC DTG + [TDF or TAF]/FTC Resistance to DRV and DTG emerges slowly; transmitted resistance to DRV is rare and transmitted resistance to DTG has not been reported to date In chronic HIV infection: Include a drug with a high genetic barrier to resistance in the 1 st -line regimen, such as boosted PI or DTG In primary HIV infection: Preference should be given to starting a boosted PI to increase the resistance barrier An INI should also be included to induce rapid viral load suppression Consider DRV/r or /c or INI + [TDF or TAF] + FTC *Neither situation is covered by the WHO guidelines 4 LPV, lopinavir PEP, post-exposure prophylaxis PrEP, pre-exposure prophylaxis Adapted from: 1. Günthard HF, et al. JAMA 2016;316: ; 2. DHHS Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents, October 2017; 3. EACS Guidelines Version 9.0, October WHO Consolidated Guidelines on the Use of ARV Drugs for Treating and Preventing HIV Infection, July 2016
16 HIV-1 RNA <50 c/ml, % Results: Snapshot Outcomes at Week 48 for GEMINI-1 and -2 Virologic outcome Adjusted treatment difference (95% CI) a GEMINI-1 DTG + 3TC (N=356) DTG + TDF/FTC (N=358) GEMINI-2 DTG + 3TC (N=360) DTG + TDF/FTC (N=359) DTG DTG + TDF/FTC + TDF/FTC DTG + 3TC GEMINI GEMINI Virologic success Virologic nonresponse No virologic data Percentage-point difference DTG + 3TC is non-inferior to DTG + TDF/FTC with respect to proportion <50 c/ml at Week 48 (snapshot, ITT-E population) in both studies a Based on Cochran-Mantel-Haenszel stratified analysis adjusting for the following baseline stratification factors: plasma HIV-1 RNA ( 100,000 c/ml vs >100,000 c/ml) and CD4+ cell count ( 200 cells/mm 3 vs >200 cells/mm 3 ). Adapted from: Cahn et al. AIDS 2018; Amsterdam, the Netherlands. Slides TUAB0106LB. 22nd International AIDS Conference; July 23-27, 2018; Amsterdam, the Netherlands
17 Results: Snapshot Analysis by Visit: Pooled ITT-E Population GEMINI-1 and -2 HIV-1 RNA <50 c/ml, % CD4+ cell count (cells/mm 3 ) DTG + 3TC (n=716) DTG + TDF/FTC (n=717) Adjusted mean change DTG + 3TC 224 from baseline at Week 48 a DTG + TDF/FTC Study visit a Calculated from a repeated measures model adjusting for study, treatment, visit (repeated factor), baseline plasma HIV -1 RNA, baseline CD4+ cell count, treatment and visit interaction, and baseline CD4+ cell count and visit interaction. Adapted from: Cahn et al. AIDS 2018; Amsterdam, the Netherlands. Slides TUAB0106LB. 22nd International AIDS Conference; July 23-27, 2018; Amsterdam, the Netherlands
18 LATTE-2 Week 96 Results HIV-1 RNA <50 c/ml by Snapshot (ITT-ME) Oral CAB induction period (ITT-ME population) Maintenance period BL, baseline; CAB, cabotegravir; IM, intramuscular; ITT-ME, intent-to-treat maintenance exposed; Q4W, every 4 weeks; Q8W, every 8 weeks. Adapted from: Margolis et al. Lancet Sep 23;390(10101):
19 The future of Integrase Inhibitors New molecules New formulations including injectables New 2-drug regimens Safety in pregnancy Real world long term data
20 Intergrases and pregnancy The Tsepamo Study started in August 2014 Birth Outcomes Surveillance Funding: NIH/NICHD (R01, R Shapiro PI) Primary aims:: (1) Evaluate adverse birth outcomes by HIV-status and ART regimen (2) Determine if there is an increased risk of neural tube defects (NTDs) among infants exposed to efavirenz (EFV) from conception
21 NTD Prevalence Difference by Exposure
22 SWORD-1 and -2: Safety Profile at Week 48 and Week 100 Safety profile of late switch group was similar to early-switch group (48 weeks post-switch) Early-switch group DTG + RPV Week 48 1 (n=513) DTG + RPV Week (n=513) Late-switch group DTG + RPV Week (n=477) n (%) Any AE 395 (77) 453 (88) 386 (81) Any AE occurring in 10% of subjects in any group Viral upper RTI * 77 (15) 49 (10) Headache 41 (8) 59 (12) 29 (6) Upper RTI * 24 (5) 51 (10) 35 (7) Nasopharyngitis * 49 (10) 8 (2) 8 (2) Drug-related AEs 97 (19) 103 (20) 56 (12) Drug-related AEs occurring in 2% of subjects in any group Headache 11 (2) 11 (2) 8 (2) Nausea 7 (1) 8 (2) 5 (1) Serious AEs 27 (5) 58 (11) 30 (6) Fatal AEs 1 (<1) 1 (<1) 0 AEs leading to discontinuation 17 (3) 34 (7) 15 (3) Psychiatric disorders 7 (1) 12 (2) 5 (1) *Preferred term coding based on MedDRA version 20.1 rather than 19.1 (used in the Week 48 analysis), cold and common cold changed in preferred term from nasopharyngitis to viral upper RTI ; No grade 2 4 drug-related AEs of 2% frequency in any group; Subject may have had >1 AE that led to discontinuation; Grouped term includes multiple AEs. Psychiatric AEs that led to discontinuation in the early-switch group were anxiety (n=4), suicidal ideation (n=4), insomnia (n=2), depression (n=2), affective disorder, depressed mood, nightmare, and completed suicide (n=1 each); those in the late-switch group were insomnia (n=3), depression (n=2), abulia, confusional state, loss of libido, major depression, and suicidal ideation (n=1 each) RTI, respiratory tract infection Adapted from1. Llibre J, et al. Lancet 2018;391: Aboud M, et al. IAS Poster THPEB047
Disclosures (last 12 months)
HIV Research What s in the Pipeline? Samir K. Gupta, MD, MS Division of Infectious Diseases Indiana University School of Medicine Disclosures (last 12 months) Independent research grant funding by NIH/NHLBI,
More informationRESEARCH B/F/TAF in Treatment-Naïve HIV-1 and HIV-1 RNA Suppressed Switch Patients
RESEARCH B/F/TAF in Treatment-Naïve HIV-1 and HIV-1 RNA Suppressed Switch Patients Kirsten White Gilead Sciences, Inc., Foster City, CA Background Bictegravir (BIC; B) is a novel, unboosted integrase strand
More informationState of the ART: Integrase Inhibitors Clinical Data. Juan Berenguer Hospital General Universitario Gregorio Marañón (IiSGM) Madrid, Spain
State of the ART: Integrase Inhibitors Clinical Data Juan Berenguer Hospital General Universitario Gregorio Marañón (IiSGM) Madrid, Spain Disclosures Consulting fees and honoraria Gilead, Janssen, MSD,
More informationMore Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD
More Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD More Options, Some Opinions: Initial Therapies for HIV Judith S. Currier, MD University of California Los Angeles Los Angeles,
More informationAntiretroviral Therapy: What to Start
FLOWED: 05-14-2015 Chicago, IL: May 18, 2015 Antiretroviral Therapy: What to Start Eric S. Daar, MD Professor of Medicine David Geffen School of Medicine University of California Los Angeles Los Angeles,
More informationDRUGS IN PIPELINE. Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015
DRUGS IN PIPELINE Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015 N(t)RTI The Development of TAF TAF Delivers the High Potency of TDF While Minimizing Off- Target Kidney and Bone Side Effects
More informationHIV Treatment: New and Veteran Drugs Classes
HIV Treatment: New and Veteran Drugs Classes Jonathan M Schapiro, MD National Hemophilia Center Stanford University School of Medicine Rome, March 2013 Overview Many excellent antiretroviral agents are
More informationDidactic Series. CROI New Antiretroviral Therapies. Daniel Lee, MD Clinical Professor of Medicine UCSD Medical Center Owen Clinic July 14, 2016
Didactic Series CROI 2016 - New Antiretroviral Therapies Daniel Lee, MD Clinical Professor of Medicine UCSD Medical Center Owen Clinic July 14, 2016 This project is supported by the Health Resources and
More informationComprehensive Guideline Summary
Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and
More informationThe Integrase Inhibitor Drug Class: A Comparative Clinical Review
The Integrase Inhibitor Drug Class: A Comparative Clinical Review Ian Frank Professor of Medicine University of Pennsylvania Philadelphia, PA USA franki@pennmedicine.upenn.edu Disclosure Gilead, ViiV/GlaxoSmithKline:
More informationARVs in Development: Where do they fit?
The picture can't be displayed. ARVs in Development: Where do they fit? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker
More informationThe next generation of ART regimens
The next generation of ART regimens By Gary Maartens Presented by Dirk Hagemeister Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Current state
More informationActualización y Futuro en VIH
Actualización y Futuro en VIH Dr. Santiago Moreno Servicio de Enfermedades Infecciosas Hospital U. Ramón y Cajal. Universidad de Alcalá. IRYCIS. Madrid Agenda Control of the HIV-epidemic Coinfections Antiretroviral
More informationHIV Update Allegra CPD Day Program Port Elizabeth Dr L E Nojoko
HIV Update 2014 Allegra CPD Day Program Port Elizabeth 12-02-2014 Dr L E Nojoko Global estimates for adults and children 2011 People living with HIV 34.0 million [31.4 million 35.9 million] New HIV infections
More informationStarting and Switching ART: 2016
Starting and Switching ART: 2016 Luke Jerram Rajesh T. Gandhi, M.D. Massachusetts General Hospital Harvard Medical School Disclosures: grant support from EBSCO, Gilead, Merck, Viiv Thanks to Henry Sunpath,
More informationHIV Treatment Update. Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London
HIV Treatment Update Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London Guidelines Nuke sparing Nukes Efavirenz placement as the gold standard ARV Role
More informationSINGLE. Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects
SINGLE Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects SE/HIV/0023/14 January 2014 PHASE III DTG TRIALS IN TREATMENT-NAÏVE ADULT SUBJECTS WITH HIV SINGLE 1 N=833 Phase III non-inferiority,
More informationClinical support for reduced drug regimens. David A Cooper The University of New South Wales Sydney, Australia
Clinical support for reduced drug regimens David A Cooper The University of New South Wales Sydney, Australia Clinical support for reduced drug regimens First line optimisation Virological failure New
More informationSwitching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches
Switching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches Harry W. Lampiris, MD Chief, Infectious Disease Section, San Francisco VA Medical Center Professor
More informationAntiretroviral Treatment Strategies: Clinical Case Presentation
Antiretroviral Treatment Strategies: Clinical Case Presentation Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan Chia-Jui, Yang M.D Disclosure No conflicts of interests.
More informationKimberly Adkison, 1 Lesley Kahl, 1 Elizabeth Blair, 1 Kostas Angelis, 2 Herta Crauwels, 3 Maria Nascimento, 1 Michael Aboud 1
Pharmacokinetics of Dolutegravir and Rilpivirine After Switching to the Two-Drug Regimen From an Efavirenz- or Nevirapine- Based Antiretroviral Regimen: SWORD-1 & -2 Pooled PK Analysis Kimberly Adkison,
More informationSecond-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Second-Line Therapy David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases University of Washington Presentation
More informationTim Horn Deputy Executive Director, HIV & HCV Programs Treatment Action Group NASTAD Prevention and Care Technical Assistance Meeting Washington, DC
Tim Horn Deputy Executive Director, HIV & HCV Programs Treatment Action Group NASTAD Prevention and Care Technical Assistance Meeting Washington, DC July 19, 2017 Pipeline is robust! Several drugs, coformulations,
More informationHIV 101. Applications of Antiretroviral Therapy
HIV 101. Applications of Antiretroviral Therapy Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University of Alabama at Birmingham Birmingham,
More informationHIV - Therapy Principles
HIV - Therapy Principles Manuel Battegay and Christine Katlama Basel, Switzerland and Paris, France Disclosure MB has received honoraria for advisory board participation from Gilead, MSD, Pfizer, ViiV
More informationThird Agent Advantages Disadvantages. Component Tenofovir/emtricitabine (TDF/FTC) 300/200 mg (coformulated with EFV as Atripla) 1 tab once daily
Table I. Recommended and Alternative Antiretroviral Regimens (DHHS Guidelines, May 1, 2014) Recommended Regimens Nucleoside Analog Reverse Transcriptase Inhibitor (NRTI) Third Agent Advantages Disadvantages
More informationSimplifying HIV Treatment Now and in the Future
Simplifying HIV Treatment Now and in the Future David M. Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine Nothing Disclosure 1 Objectives List current first line
More informationAre the current doses of ARV correct. Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine
Are the current doses of ARV correct Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine Can we lower doses of HIV meds safely? Consensus Panel in Alexandria
More informationACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals
Antiretroviral Medications: What you need to know Jason J. Schafer, PharmD, MPH, BCPS, AAHIVP Associate Professor, Department of Pharmacy Practice Jefferson College of Pharmacy, Thomas Jefferson University
More informationVIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects
VIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects IL/DLG/0040/14 June 2014 GSK (Israel) Ltd. Basel 25, Petach Tikva. Tel-03-9297100 Medical information service: il.medinfo@gsk.com
More informationIntegrase Strand Transfer Inhibitors on the Horizon
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Integrase Strand Transfer Inhibitors on the Horizon David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, University of Washington Presentation
More informationTDF containing ART: Efficacy and Safety. Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia
TDF containing ART: Efficacy and Safety Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia 1 Indications Treatment of HIV-1 in combination with other antiretroviral
More informationViiV Healthcare investor & analyst update
ViiV Healthcare investor & analyst update 15 February 2017 David Redfern, GSK Chief Strategy Officer and Chairman, ViiV Healthcare Dr. Dominique Limet, Chief Executive Officer, ViiV Healthcare Dr. John
More informationGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More informationART: The New, The Old and The Ugly
ART: The New, The Old and The Ugly Our Current ARVS The Nucleoside/ Nucleotide Reverse Transcriptase Inhibitors (NRTIs/ NtRTIs) Abacavir Emtricitabine Lamivudine Stavudine Tenofovir Zidovudine The Non-Nucleoside
More informationTwo Drug Regimens Pros and Cons. Jürgen Rockstroh Department of Medicine I University Hospital Bonn, Bonn, Germany
Two Drug Regimens Pros and Cons Jürgen Rockstroh Department of Medicine I University Hospital Bonn, Bonn, Germany HIV Clinical Forum, Moscow, Russia, Friday 23 rd November 2018 Conflict of Interest: JKR
More informationResistance Analyses of Integrase Strand Transfer Inhibitors within Phase 3 Clinical Trials of Treatment-Naive Patients
Viruses 2014, 6, 2858-2879; doi:10.3390/v6072858 Review OPEN ACCESS viruses ISSN 1999-4915 www.mdpi.com/journal/viruses Resistance Analyses of Integrase Strand Transfer Inhibitors within Phase 3 Clinical
More informationNew HIV EACS and Italian Guidelines
Original Article HIV correlated pathologies and other infections Marco Borderi New HIV EACS and Italian Guidelines Infectious Disease Unit - S. Orsola-Hospital - University of Bologna Corresponding author:
More informationSELECTING THE BEST ART FOR EACH PATIENT
SELECTING THE BEST ART FOR EACH PATIENT Corklin R Steinhart, MD, PhD Head, Global Medical Directors ViiV Healthcare CNVX/HIVP/0025/16 5th Asian Conference on Hepatitis & AIDS 第五届亚洲肝炎与艾滋病学术会议 28-29 May
More informationHIV Treatment: State of the Art 2013
HIV Treatment: State of the Art 2013 Daniel R. Kuritzkes, MD Chief, Division of Infectious Diseases Brigham and Women s Hospital Professor of Medicine Harvard Medical School Success of current ART Substantial
More informationDisclosures. Update on HIV Drug Therapy: A Case based Discussion. Case # 1: Dr. Grant has received grant support from BMS, Gilead, Janssen, and Viiv
Disclosures Update on HIV Drug Therapy: A Case based Discussion Dr. Grant has received grant support from BMS, Gilead, Janssen, and Viiv Philip Grant Assistant Professor Division of Infectious Diseases
More informationDolutegravir-Rilpivirine (Juluca)
Dolutegravir-Rilpivirine (Juluca) David H. Spach, MD Clinical Director, MW AETC Professor of Medicine Division of Infectious Diseases University of Washington Last Updated: November 30, 2017 ANTIRETROVIRAL
More informationWhat's new in the WHO ART guidelines How did markets react?
WHO 2013 ARV Guidelines What's new in the WHO ART guidelines How did markets react? Dr. J. Perriëns Coordinator, HIV Technology and Commodities HIV department, WHO, Geneva When to start in adults Starting
More informationSelecting an Initial Antiretroviral Therapy (ART) Regimen
Selecting an Initial Antiretroviral Therapy (ART) Regimen An HIV Diagnosis is a Call to Action In support of the NYSDOH AIDS Institute s January 2018 call to action for patients newly diagnosed with HIV,
More informationPharmacological considerations on the use of ARVs in pregnancy
Pharmacological considerations on the use of ARVs in pregnancy 11 th Residential Course on Clinical Pharmacology of Antiretrovirals Torino, 20-22 January 2016 Prof. David Burger, PharmD, PhD david.burger@radboudumc.nl
More informationPrima linea: dovremmo evitare i PI nella terapia di prima linea per i loro effetti non desiderati? Giuseppina Liuzzi
6 th INFECtivology TOday Paestum 15-16 -17 maggio 2014 Prima linea: dovremmo evitare i PI nella terapia di prima linea per i loro effetti non desiderati? Giuseppina Liuzzi Istituto Nazionale per le Malattie
More informationDidactic Series. Switching Regimens in the Setting of Virologic Suppression
Didactic Series Switching Regimens in the Setting of Virologic Suppression Craig Ballard, PharmD, AAHIVP UC San Diego Health Owen Clinic June 14 th, 2018 1 Learning Objectives 1) Describe DHHS guidelines
More informationTreating HIV in 2018 Interactive Cases From the Clinic(ians)
Slide 1 of 51 Treating HIV in 2018 Interactive Cases From the Clinic(ians) Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University of Alabama
More informationFirst line ART Rilpirivine A New NNRTI. Chris Jack Physician, Durdoc Centre ethekwini
First line ART Rilpirivine A New NNRTI Chris Jack Physician, Durdoc Centre ethekwini Overview: Rilpirivine an option for ARV Naïve patients History Current guidelines Efficacy and Safety Tolerability /
More informationCROI 2017 Review: Novel ART Strategies
Mountain West AIDS Education and Training Center CROI 2017 Review: Novel ART Strategies Brian R. Wood, MD Assistant Professor of Medicine Medical Director, Mountain West AETC ECHO Telehealth March 2, 2017
More informationAntiretroviral Drugs
Antiretroviral Drugs Dr Paddy Mallon UCD HIV Molecular Research Group Associate Dean for Research and Innovation UCD School of Medicine and Medical Science paddy.mallon@ucd.ie UCD School of Medicine &
More informationPanelists Melanie Thompson Jeffrey Lennox Wendy Armstrong Jonathan Li
Slide 1 of 51 Interactive ART Cases From the Clinic(ians): Case-Based Panel Discussion Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University
More informationHIV Treatment Evolution. Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare
HIV Treatment Evolution Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare Overview of the Evolution of Antiretroviral Therapy Early Treatment 1987
More informationThe use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines
The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines I. Boucoiran, T. Lee, K. Tulloch, L. Sauve, L. Samson, J. Brophy, M. Boucher and D. Money For and
More informationUpdate on HIV Drug Resistance. Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School
Update on HIV Drug Resistance Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Learning Objectives Upon completion of this presentation, learners
More informationThe ART of Managing Drug-Drug Interactions in Patients with HIV
The ART of Managing Drug-Drug Interactions in Patients with HIV Bradley L. Smith, Pharm.D. smith.bradley1@mayo.edu Pharmacy Grand Rounds December 19, 2017 2017 MFMER slide-1 Presentation Objectives Describe
More informationDolutegravir: Pros and Cons (Are There Any Cons?)
Mountain West AIDS Education and Training Center Dolutegravir: Pros and Cons (Are There Any Cons?) Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical Director, MW AETC
More informationUpdates to the HHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV Updated October 17, 2017
Mountain West AIDS Education and Training Center Updates to the HHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV Updated October 17, 2017 26 October 2017 Hillary
More informationContinuing Education for Pharmacy Technicians
Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationPrinciples of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
More informationReduced Drug Regimens
Dr. Jose R Arribas @jrarribas Financial disclosures JOSE R ARRIBAS Research Support: Speaker s Bureau: Viiv, Janssen, Abbvie, BMS, Gilead, MSD Board Member/Advisory Panel: Merck, Gilead Stock/Shareholder:
More informationOptimizing Clinical Utility of Integrase Inhibitors. Anton Pozniak MD FRCP
Optimizing Clinical Utility of Integrase Inhibitors Anton Pozniak MD FRCP INSTIs-Characteristics Rapid viral load decline Low rates resistance/ Transmitted Resistance Less chance of side effects Less pills,
More informationACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals
Initial Therapy for Antiretroviral Naïve HIV Infected Patients Michelle Cespedes, MD, MS Associate Professor of Medicine Division of Infectious Disease Icahn School of Medicine at Mount Sinai Disclosures
More informationCase 1 continued. Case 1 (cont) 12/8/16. MMAH Debate Panel Thursday, December 8, Case 1
MMAH Debate Panel Thursday, December 8, 2016 Case 1 HPI 55 yo man with newly diagnosed HIV initiates care in your clinic. His CD4+ cell count is 600, with HIV VL=90,000 copies/ml. He is asymptomatic at
More informationCrafting an ART Regimen for Initiation or Salvage: Are NRTI s Necessary?
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Crafting an ART Regimen for Initiation or Salvage: Are NRTI s Necessary? Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical
More informationSTRIBILD (aka. The Quad Pill)
NORTHWEST AIDS EDUCATION AND TRAINING CENTER STRIBILD (aka. The Quad Pill) Brian R. Wood, MD Medical Director, NW AETC ECHO Assistant Professor of Medicine, University of Washington Presentation prepared
More informationSwitching antiretroviral therapy to safer strategies based on integrase inhibitors. Pedro Cahn
Switching antiretroviral therapy to safer strategies based on integrase inhibitors Pedro Cahn Disclosures Research Grants: Abbvie-Merck-Richmond-ViiV Advisory boards: Merck-Sandoz-ViiV Switching in Virologically
More informationPharmacologic Characteristics and Delivery Options for Integrase Inhibitors
Pharmacologic Characteristics and Delivery Options for Integrase Inhibitors Courtney V. Fletcher, Pharm.D. Dean, College of Pharmacy Professor, Department of Pharmacy Practice and Division of Infectious
More informationInvestigational Approaches to Antiretroviral Therapy
Investigational Approaches to Antiretroviral Therapy Rajesh T. Gandhi, MD Massachusetts General Hospital Professor of Medicine Harvard Medical School Boston, Massachusetts Learning Objectives After attending
More informationResistance Characteristics of Integrase Inhibitors
Resistance Characteristics of Integrase Inhibitors Madrid, November 2016 Jonathan M Schapiro, MD National Hemophilia Center, Israel Stanford University School of Medicine, USA Disclaimer Presentation includes
More informationResistance to Integrase Strand Transfer Inhibitors
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Resistance to Integrase Strand Transfer Inhibitors David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases
More informationIntroduction. Cahn et al. Andean Pacific HIV Clinical Forum 2017; Santiago, Chile. Abstract 2.
Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) Fixed Dose Combination (FDC) Compared With Ritonavir- Boosted Atazanavir (ATV/r) Plus Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) in
More informationThis graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts
1 2 This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts decreased. This period of acute infection or serocnversion
More informationKees Brinkman OLVG- Amsterdam The Netherlands
integrase inhibitors in clinical practice in the Netherlands HIV Clinical Forum 2018 Kees Brinkman OLVG- Amsterdam The Netherlands Disclosures relevant activities to dislose companies advisory boards Gilead
More informationClinical use of Integrase Inhibitors. Eugenia Negredo Fundació de la Lluita contra la Sida Hospital Germans Trias i Pujol Spain
Clinical use of Integrase Inhibitors Eugenia Negredo Fundació de la Lluita contra la Sida Hospital Germans Trias i Pujol Spain Septiembre 218 Disclosures Research grants: Gilead (GoShape), ViiV Advisory
More informationInvestigational Approaches to Antiretroviral Therapy
Investigational Approaches to Antiretroviral Therapy Rajesh T. Gandhi, MD Massachusetts General Hospital Professor of Medicine Harvard Medical School Boston, Massachusetts Learning Objectives After attending
More informationTreatment update. Bronagh McBrien June 2016
Treatment update Bronagh McBrien June 2016 Speaker Name Bronagh McBrien Statement Received educational funding and support from Gilead, Merck, Boehringer Ingelheim, Janssen-Cilag Date : 27 June 2016 BHIVA
More informationBon Usage des Antirétroviraux dans l Infection par le VIH
Bon Usage des Antirétroviraux dans l Infection par le VIH Pr. Jean-Michel Molina CHU St Louis, Assistance Publique Hôpitaux de Paris, INSERM U941 et Université Paris 7 Diderot, France 1 Liens d Intérêt
More informationAntiretroviral Therapy in 2016
Antiretroviral Therapy in 2016 Joel Gallant, MD, MPH Southwest CARE Center Santa Fe, NM University of New Mexico School of Medicine Johns Hopkins University School of Medicine Disclosures Consulting, Advisory
More information12th European AIDS Conference / EACS ARV Therapies and Therapeutic Strategies A CME Newsletter
EACS 2009 11-14, November 2009 Cologne, Germany Course Director Jürgen K. Rockstroh, MD Co-Chairman, 12th European AIDS Conference Professor, University of Bonn Bonn, Germany Faculty Calvin Cohen, MD,
More informationACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals
ACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals ACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals Are You Ready? New Drugs Are on the Way!
More informationWhat is the Virologic Support for Two-Drug Regimens?
What is the Virologic Support for Two-Drug Regimens? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker has received consulting
More informationL infettivologia del 3 millennio: AIDS ed altro
L infettivologia del 3 millennio: AIDS ed altro VI Convegno Nazionale 15-16 -17 maggio 2014 Centro Congressi Hotel Ariston Paestum (SA) Nuove molecole ad azione anti-hiv Annalisa Saracino Clinica Malattie
More informationClinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in treatment of HIV positive adults and adolescents
Clinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in treatment of HIV positive adults and adolescents 1 Clinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in
More informationWEB ANNEX B. SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS ASSESSING FIRST-LINE ART TREATMENTS
WEB ANNEX B. SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS ASSESSING FIRST-LINE ART TREATMENTS Steve Kanters, Jeroen Jansen, Michael Zoratti, Jamie Forrest, Brittany Humphries, Jonathon Campbell
More informationSwitching antiretroviral therapy to safer strategies based on integrase inhibitors
Switching antiretroviral therapy to safer strategies based on integrase inhibitors Dr Paddy Mallon UCD HIV Molecular Research Group UCD School of Medicine paddy.mallon@ucd.ie UCD School of Medicine & Medical
More informationCase # 1. Case #1 (cont d)
Antiretroviral Therapy Management: Expert Panel Discussion George Beatty Susa Coffey Steve O Brien December 3, 2011 Moderated by Annie Luetkemeyer Case # 1 38 y.o. man, CD4 =350, VL=340K, new to your clinic
More informationTerapia Antirretroviral en la Infección por el VIH (problemas, retos y soluciones) Dr. Jose R
Terapia Antirretroviral en la Infección por el VIH (problemas, retos y soluciones) Dr. Jose R Arribas @jrarribas Disclosures Speaker s Bureau: Gilead Board Member/Advisory Panel: MSD, Gilead, Janssen,
More informationAntiretroviral Therapy: Panel Discussion
disclosures Antiretroviral Therapy: Panel Discussion Medical Management of HIV December 9, 217 Panelists: Harry Lampiris, MD; Annie Luetkemeyer, MD; Carina Marquez, MD Moderator: Oliver Bacon, MD none
More informationManagement of ART Failure. EACS Advanced HIV Course 2015 Dr Nicky Mackie
Management of ART Failure EACS Advanced HIV Course 2015 Dr Nicky Mackie Outline Defining treatment success Defining treatment failure Reasons for ART failure Management of ART failure Choice of second
More informationCabotegravir Long-Acting (LA) Injectable Nanosuspension Bill Spreen, for ViiV Healthcare & GSK Development Team. 17 th HIV-HEPPK June 2016
Cabotegravir Long-Acting (LA) Injectable Nanosuspension Bill Spreen, for ViiV Healthcare & GSK Development Team RPV CAB CAB RPV 1 June 2016 Cabotegravir Long-Acting Nanosuspension CAB is an investigational
More information2-Drug regimens in HIV Anton Pozniak MD FRCP
2-Drug regimens in HIV Anton Pozniak MD FRCP Advantages Cost Dual Therapy Toxicities of Nukes CV risk, bone, renal disease Smaller STRs Keep drugs for later etc. Dual Therapy-Talking Points - What are
More informationVIKING STUDIES. Efficacy and safety of dolutegravir. treatment-experienced subjects
VIKING STUDIES Efficacy and safety of dolutegravir treatment-experienced subjects (DTG) in UK/DLG/0083/14e(2) Date of preparation: February 2017 Prescribing information is available at the end of this
More informationCabotegravir + Rilpivirine as Long-Acting Maintenance Therapy: LATTE-2 Week 32 Results
Slide 1 Cabotegravir + Rilpivirine as Long-Acting Maintenance Therapy: LATTE-2 Week 32 Results David A. Margolis, 1 Juan Gonzalez-Garcia, 2 Hans-Jürgen Stellbrink, 3 Joe Eron, 4 Yazdan Yazdanpanah, 5 Sandy
More informationIntroduction to HIV Drug Resistance. Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School
Introduction to HIV Drug Resistance Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School Objectives 1. Describe the epidemiology of HIV drug resistance in sub-saharan Africa. 2.
More informationCROI 2013: New Drugs for Treatment and PrEP
NORTHWEST AIDS EDUCATION AND TRAINING CENTER CROI 2013: New Drugs for Treatment and PrEP Brian R. Wood, MD Medical Director, NW AETC Project ECHO Assistant Professor of Medicine, University of Washington
More informationManagement of patients with antiretroviral treatment failure: guidelines comparison
The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral
More informationDidactic Series. CROI 2014 Update. March 27, 2014
Didactic Series CROI 2014 Update Christian Ramers, MD, MPH Family Health Centers of San Diego Ciaccio Memorial Clinic Jacqueline Peterson Tulsky, MD UCSF Positive Health Program at SFGH Medical Director,
More informationWhat next? Francois Venter. ART new drugs, new studies. Wits Reproductive Health & HIV Institute
Thanks: Polly Clayden, Francesca Conradie, Loyd Mulenga, Gary Maartens, Andrew Hill, David Ripin, Elli Katabira, Chris Duncombe, Nathan Ford, Marco Vitoria, WHO Industry: Gilead, Janssen, ViivV Abbott,
More information